新 proposed 第九版 N 描述符中 PET/CT 定义隐匿性淋巴结转移的生存影响:一项多中心研究
该多中心回顾性研究纳入 3565 例术前行 PET/CT 并接受手术切除的非小细胞肺癌患者,分析 PET/CT 定义隐匿性 N2 转移预后较好的原因及其在新 proposed 第九版 N 描述符中的生存影响。结果显示隐匿性 N2 转移中单站受累比例显著高于明显 N2 转移(61.3% vs 41.9%,p < .001),隐匿性与明显 N2a、N2b 的生存分别相当,而单站受累预后优于多站受累,支持第九版 N 描述符的合理性。
要点
- 隐匿性 N2 转移单站受累比例为 61.3%(117/191),明显 N2 转移为 41.9%(83/198),差异显著(p < .001)。
- 隐匿性 N2a 与明显 N2a、隐匿性 N2b 与明显 N2b 的生存分别相当(校正 p > .20)。
- 单站受累预后优于多站受累:隐匿 N2 的 5 年 OS 为 62.7% vs 50.1%(校正 p = .04),明显 N2 为 50.3% vs 36.2%(校正 p = .03)。
核心结论
- PET/CT 定义隐匿性 N2 转移预后较好可能归因于隐匿性 N2a 与明显 N2b 在预后和比例上的差异。
- 该外部验证为新 proposed 第九版 N 描述符的合理性和稳健性提供了实质证据。
研究设计与样本
- 多中心回顾性纳入 3565 例术前行 PET/CT 并接受手术切除的非小细胞肺癌患者。
- 采用 Kaplan-Meier 法和 Cox 比例风险模型进行生存分析。
主要发现
- 隐匿性 N2 转移单站受累比例为 61.3%(117/191),明显 N2 转移为 41.9%(83/198),差异显著(p < .001)。
- 隐匿性 N2a 与明显 N2a、隐匿性 N2b 与明显 N2b 的生存分别相当(校正 p > .20)。
- 隐匿性 N2 转移中单站受累 5 年 OS 为 62.7%,多站受累为 50.1%(校正 p = .04)。
- 明显 N2 转移中单站受累 5 年 OS 为 50.3%,多站受累为 36.2%(校正 p = .03)。
- 病理 N2 人群 Cox 回归分析显示多站受累是比隐匿性淋巴结转移更稳健的预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To elucidate the potential reasons for the favourable prognosis of positron emission tomography/computed tomography (PET/CT)-defined occult N2 metastasis and its survival effect in the context of the newly proposed ninth edition N descriptors. METHODS: A total of 3565 patients who underwent preoperative PET/CT and surgical resection for non-small cell lung cancer were retrospectively included. Survival analysis was conducted using the Kaplan-Meier method and Cox proportional hazards model. RESULTS: The incidence of single-station involvement was significantly higher (p < .001) in occult N2 metastasis (117/191, 61.3%) compared to evident N2 metastasis (83/198, 41.9%). The survival rates of patients with occult N2a (single-station N2 involvement) and occult N2b (multiple-station N2 involvement) were comparable to those of patients with clinically evident N2a and N2b, respectively (adjusted p >.20 for all). Conversely, single-station involvement was associated with a markedly superior prognosis than multiple-station involvement, whether for patients with occult N2 metastasis (5-year overall survival [OS]: 62.7% vs 50.1%, adjusted p = .04) or patients with clinically evident N2 metastasis (5-year OS: 50.3% vs 36.2%, adjusted p = .03). Cox regression analysis of the pathological N2 population further indicated that multiple-station involvement was a more robust prognostic factor than occult lymph node metastasis. CONCLUSIONS: The favourable prognosis of PET/CT-defined occult N2 metastasis may be attributed to the discrepancy in prognosis and proportion between occult N2a and clinically evident N2b. This external validation provided substantial evidence supporting the reasonableness and robustness of the newly proposed ninth edition N descriptors.
引用
- Shen X, Chen T, Yu J, et al. Survival effect of PET/CT-defined occult lymph node metastasis in the newly proposed ninth edition N descriptors: a multicentre study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40986090. doi:10.1007/s00259-025-07544-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。